Hi Surges,"Since we have an exclusive collaboration for those...

Hi Surges,

"Since we have an exclusive collaboration for those applications, one wonders wether our ETP technologies are still available for other partners, raising the question wether the FMCG1 would indeed use the eM-Patch technology and the FMCG2 the newly added FIM technology patents."

Glyn advised me only 2 weeks ago on June 6, "OBJ is actively working with a number of FMCG (fast moving consumer goods) companies at this time and there are other companies as well".

The exclusivity clause of their collaboration agreement with GSK does not extend outside of the Oral Healthcare market so there remains no effect to their other partnership collaborations or the availability of all 3 technology platforms for licensing to other companies.

"OBJ has an extensive portfolio of "Field-Of-Use" patents covering all the major commercial areas of interest to OBJ's partner companies. These are designed to provide OBJ broad exclusivity and allow the efficient and effective licensing across all key markets."

"Field-of-use licensing provides the licensor with greater control over the use of its intellectual property, while maximizing the use and value of the technology. In order to maximize the use of a given technology, managers will have some additional work to do as they identify, negotiate with, and manage more than one licensee. Special issues related to multiple licensees in distinct or overlapping fields will have to be handled with forethought and a balancing of interests.

When is field-of-use licensing worth the extra effort?

When more than one company is needed to fully develop a technology�s potential, when different licensees are needed to address different markets, or when field-of-use licensing has the potential to significantly increase the financial return from a technology. In all of these situations, field-of-use licensing can produce better results for everyone involved. Click here IP Handbook - Field-of-use licensing